Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 124-131

  Zolnierczyk, Jolanta D ^a   Błoński, Jerzy Z ^b   Robak, Tadeusz ^b   Kiliańska, Zofia M ^a   Wȩsierska Gadek, Józefa ^c  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antileukemia therapy; Apoptosis, apoptosis and cell cycle related proteins; B cell chronic lymphocytic leukemia; Cytotoxicity

Indexed keywords

CLADRIBINE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; FLUDARABINE; MAFOSFAMIDE; PROCASPASE 9; PROTEIN BAX; PROTEIN MCL 1; ROSCOVITINE;

APOPTOSIS; B CELL LEUKEMIA; CELL KILLING; CELL VIABILITY; CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LEUKEMIA CELL; MALE;

EID: 69149093799     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04903.x     Document Type: Conference Paper

References (50)

1. Rozman, C. E. Montserrat. 1995. Chronic lymphocytic leukemia. N. Engl. J. Med. 333 : 1052 1057.
2. Caligaris-Cappio, F. 2003. Role of the microenvironment in chronic lymphocytic leukemia. Br. J. Hematol. 123 : 380 388.
3. Granziero, L. et al. 2001. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 : 2777 2783.
4. Messmer, B.T. et al. 2005. In vivo measurements document the dynamic, cellular kinetics of chronic lymphocytic B cells. J. Clin. Invest. 115 : 755 764.
5. Dighiero, G. 2005. Cell biology and prognosis. Hematology Am. Soc. Educ. Program 2005 : 278 284.
6. Caligaris-Cappio, F. 1996. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 87 : 2615 2620.
7. Bannerji, R. J.C. Byrd. 2000. Update on the biology of chronic lymphocytic leukemia. Curr. Opin. Oncol. 12 : 22 29.
8. Ferrajoli, A. S.M. O'Brien. 2004. Treatment of chronic lymphocytic leukemia. Semin. Oncol. 31 : 60 65.
9. Petlickovski, A. et al. 2005. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 105 : 4820 4827.
10. Van Den Neste, E. et al. 2005. Old and new insight into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine. Int. J. Oncol. 27 : 1113 1124.
11. Rodriguez, A. et al. 2007. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 21 : 1984 1991.
12. Hahntow, I.N. et al. 2004. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18 : 747 755.
13. Saxena, A. et al. 2004. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am. Hematol. 75 : 22 33.
14. Packham, G. F.K. Stevenson. 2005. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114 : 441 449.
15. Sanz, L. et al. 2004. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochim. Biophys. Res. Commun. 315 : 562 567.
16. Decker, T. et al. 2004. Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target. Br. J. Hematol. 125 : 141 148.
17. Alvi, A.J. et al. 2005. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down regulation of genes involved in transcription regulation and survival. Blood 105 : 4484 4491.
18. MacCallum, D.E. et al. 2005. Seliciclib (Cyc202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65 : 5399 5407.
19. Wesierska-Gadek, J. G. Schmid. 2006. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Expert Opin. Investig. Drugs 15 : 23 38.
20. Robak, T. 2005. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 19 : 9 22.
21. Robak, T. 2005. Rituximab plus purine nucleoside analogs in the treatment of indolent lymphoid malignancies. Am. J. Cancer 4 : 279 292.
22. Byrd, J.C. et al. 2004. Chronic lymphocytic leukemia. Hematology Am. Soc. Educ. Program 2004 : 163 183.
23. Kasamon, Y.L. J.W. Flinn. 2007. Management of symptomatic, untreated lymphocytic leukemia. Blood Rev. 21 : 143 156.
24. Rai, K.R. 1998. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Semin. Oncol. 25 (suppl. 7 19 22.
25. Gandhi, V. W. Plunkett. 2001. Combination strategies for purine nucleoside analogs. In Chronic Lymphocytic Leukemias. B.D. Cheson, Ed. : 195 208. Marcel Dekker. Basel, New York.
26. Hallek, M. 2005. Chronic lymphocytic leukemia (CLL): first-line treatment. Hematology Am. Soc. Educ. Program 2005 : 285 291.
27. Keating, M. J. et al. 2003. Biology and treatment of chronic lymphocytic leukemia. Hematology Am. Soc. Educ. Program 2003 : 153 175.
28. Rogalinska, M. et al. 2004. 2-chlorodeoxyadenosine alone and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. Cancer Detect. Prev. 28 : 433 442.
29. Smolewski, P. et al. 2005. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk. Lymphoma 46 : 87 100.
30. Mansour, A. et al. 2007. Correlation of ZAP-70 expression in B-cell leukemias to the ex vivo response to a combination of fludarabine-genistein. Cancer Immunol. Immunother. 56 : 501 514.
31. Rai, K.R. et al. 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46 : 219 234.
32. Bellosillo, B. et al. 1999. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94 : 2836 2843.
33. Kobylińska, A. et al. 2006. In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combination with mafosfamide and/or mitoxantrone. Oncol. Rep. 16 : 1389 1395.
34. Lowry, O.H. et al. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 : 265 275.
35. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 : 680 685.
36. Towbin, H. et al. 1979. Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76 : 4350 4354.
37. Leary, J.J. et al. 1983. Rapid and sensitive colorimetric method for visualizing biotin-labelled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: bio-blots. Proc. Natl. Acad. Sci. USA 80 : 4045 4049.
38. + leukemic B cells; in vitro/in vivo correlations. Br. J. Haematol. 99 : 147 157.
39. Bromidge, T.J. et al. 1998. In vitro chemosensitivity of chronic lymphocytic leukemia to purine analogues - correlation with clinical course. Leukemia 12 : 1230 1235.
40. Kitada, S. et al. 1998. Expression of apoptosis - regulating proteins in chronic lymphocytic leukemia: correlation with in vitro and in vivo chemoresponses. Blood 91 : 379 389.
41. Wieder, T. et al. 2001. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 97 : 1378 1387.
42. Polyak, K. et al. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 : 59 66.
43. Sherr, C.J. 2000. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 : 3689 3695.
44. Mazumder, S. et al. 2002. Proteolytic cleavage of cyclin E leads to inactivation of associated kinase activity and amplification of apoptosis in hematopoietic cells. Mol. Cell. Biol. 22 : 2398 2409.
45. Eymin, B. et al. 1999. Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. Oncogene 18 : 4839 4847.
46. McClue S.J. et al. 2002. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102 : 463 468.
47. Liungman, M. 2001. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 60 : 785 789.
48. Fischer, P. M. A. Gianella-Borradori. 2005. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin. Investig. Drugs 14 : 4547 4577.
49. Meijer, L. E. Maymond. 2003. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 36 : 417 425.
50. McClue, S.J. I. Stuart. 2008. Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab. Dispos. 36 : 561 570.